writing diary help depression term papers a rose for emily online professional resume writing services canberra frankenstein critical essays writing essay for college application university ratio help homework company for writing research uk buy essay papers online cheap blending qualitative quantitative research methods theses dissertation
Skip to main content

Prodrugs/Drugs zur selektiven ADEPT/ADC Tumortherapie

Ref-Nr: TA-MBM-BioT-1248-SUG+ BioC-1848-SUG


Kurzfassung

Wissenschaftler der Universität Göttingen haben sowohl neue hochaktive Wirkstoffe (Drugs, mit IC50 im pico-Molar Bereich) sowie eine selektive Tumortherapie mittels deren Prodrugs entwickelt. Die Selektivität der Therapie wird durch den Antikörper erreicht, welcher sich spezifisch an die Tumorzellen bindet.


Hintergrund

Antibody tumor therapies have provided therapeutic benefit to patients with cancer, autoimmune diseases and other serious medical conditions. However, many antibodies lack sufficient intrinsic anti-tumor activity to be used as therapeutics. Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as selective antibody tumor therapeutical approaches through their prodrugs.


Bilder & Videos


Problemstellung

While a prodrug needs to have low cytotoxicity, the activated drug must on the other hand show a very high cytotoxicity in the pico-molar range. Thus, there is a high medical unmet need to have prodrugs/drugs with a big therapeutic window and extremely high and selective cytotoxicity.


Lösung

Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Advantages


Vorteile

  • New highly soluble prodrugs with low cytotoxicity.
  • Prodrug has low cytotoxicity (IC50 = 146.000 pmol/l), whereas drug is highly cytotoxic in low pico-molar range (IC50 = 0,11 pmol/l).
  • Higher cytotoxicity than actually used Doxorubicin.
  • Even less side-effects expected due to QIC50 Prodrug/Drug = 1.000.000
  • Expected improvement in safety through bigger therapeutical dosage range.
  • Specific tumor targeting through available antibodies.
  • Activation of the prodrug into cytotoxic drug occurs through the enzyme at the tumor site only (ADEPT or ADC).
  • NEW: Now including innovative linker technology to directly couple to antibody!

Anwendungsbereiche

Tumor Therapy:

  • Use of Prodrugs for an Antibody Directed Enzyme Prodrug Therapy (ADEPT) or Antibody Drug Conjugate (ADC).
  • Use of Drugs for a direct cancer therapy possible.

MBM ScienceBridge GmbH

Dr. Stefan Uhle
0551-30724 154
suhle@sciencebridge.de
www.sciencebridge.de
Adresse
Hans-Adolf-Krebs-Weg 1
37077 Göttingen



Entwicklungsstand

Präklinik


Patentsituation

  • DE DE102009051799 anhängig

Stichworte

MBM ScienceBridge, Technologietransfers, Technologieangebot, Georg-August-Universität Göttingen, Onkologe, Wirkstoff, Prodrug, Antikörpertherapie, ADEPT, ADC, Therapie, Krebs

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen